These Promising Cancer Therapies Are a Biotech "Triple Play"

On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled. Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%. And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session. It's clear that investors can do very well with the right cancer drug. But there, of course, is the rub: Finding the right cancer drug is not so easy. I'm about to show you three companies - all sound investments - running strong in the race to fight this scourge, and the one that could very well take the prize... Tags: Bellicum stock , biotech investing , biotech stocks , biotech stocks to buy , BLCM stock , cancer therapies , investing in biotech , JUNO stock , Nasdaq: BLCM , Nasdaq: JUNO , Nasdaq: TRIL , TRIL stock , Trillium stock To get full access to all Money Morning content, click here About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free . Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors. Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201. The post These Promising Cancer Therapies Are a Biotech "Triple Play" appeared first on Money Morning - We Make Investing Profitable .